Cadazolid - Actelion Pharmaceuticals

Drug Profile

Cadazolid - Actelion Pharmaceuticals

Alternative Names: ACT-179811

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Carboxylic acids; Oxazolidinones; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium-difficile-infections

Most Recent Events

  • 22 Nov 2017 Actelion suspends patient enrolment in a phase II/III trial during strategy review in Clostridium difficile infections (In neonates, In infants, In children, In adolescents) in USA (PO) (NCT03105479)
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 02 May 2017 Actelion completes a phase III trial in Clostridium difficile infections in USA, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czech Republic, Greece, Hungary, Israel, South Korea, Romania and Slovakia (NCT01983683)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top